OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity

Neurourology and Urodynamics

Volumn 32, Issue 8, 2013, Pages 1109-1115

  Rovner, Eric ^a   Dmochowski, Roger ^b   Chapple, Christopher ^c   Thompson, Catherine ^d   Lam, Wayne ^e   Haag Molkenteller, Cornelia ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d ALLERGAN PLC   (United States)

^e ALLERGAN INC   (United States)

Author keywords

multiple sclerosis; neurogenic detrusor overactivity; onabotulinumtoxinA; spinal cord injury; urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYSTOMETRY; DIARRHEA; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NEUROGENIC BLADDER; NEUROGENIC DETRUSOR OVERACTIVITY; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL; POSTVOID RESIDUAL URINE VOLUME; RHINOPHARYNGITIS; SPINAL CORD INJURY; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME; URODYNAMICS; UROSEPSIS; VULVOVAGINITIS;

MULTIPLE SCLEROSIS; NEUROGENIC DETRUSOR OVERACTIVITY; ONABOTULINUMTOXINA; SPINAL CORD INJURY; URINARY INCONTINENCE;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; SPINAL CORD INJURIES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84886421986     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22376     Document Type: Article

References (16)

1. Chancellor MB, Anderson RU, Boone TB,. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006; 85: 536-45.
2. Fowler CJ, Griffiths D, de Groat WC,. The neural control of micturition. Nat Rev Neurosci 2008; 9: 453-66.
3. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 742-50.
4. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxina in patients with urinary incontinence resulting from neurogenic detrusor overactivity. J Urol 2012; 187: 2131-9.
5. Homma Y, Batista J, Bauer S, et al. Urodynamics. In:, Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. Plymouth, UK: Plymbridge Distributors Ltd; 2002. pp. 317-72.
6. Linsenmeyer TA, Bagaria SP, Gendron B,. The impact of urodynamic parameters on the upper tracts of spinal cord injured men who void reflexly. J Spinal Cord Med 1998; 21: 15-20.
7. Shingleton WB, Bodner DR,. The development of urologic complications in relationship to bladder pressure in spinal cord injured patients. J Am Paraplegia Soc 1993; 16: 14-7.
8. Weld KJ, Graney MJ, Dmochowski RR,. Differences in bladder compliance with time and associations of bladder management with compliance in spinal cord injured patients. J Urol 2000; 163: 1228-33.
9. del Popolo G, Mencarini M, Nelli F, et al. Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: A literature overview. Spinal Cord 2012; 50: 8-13.
10. Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-7.
11. Reitz A, Stöhrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-5.
12. Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: Clinical and urodynamic results. Eur Urol 2009; 55: 705-11.
13. Game X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008; 53: 613-8.
14. Bakke A, Vollset SE,. Risk factors for bacteriuria and clinical urinary tract infection in patients treated with clean intermittent catheterization. J Urol 1993; 149: 527-31.
15. Sauerwein D,. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents 2002; 19: 592-7.
16. Stover SL, Lloyd LK, Waites KB, et al. Neurogenic urinary tract infection. Neurol Clin 1991; 9: 741-55.